Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase NA × Waldenstrom Macroglobulinemia × zanubrutinib × Clear all

Phase

Phase 2 9 Phase 4 2 Phase NA 1 Phase 3 1 Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Waldenstrom Macroglobulinemia 1 Recurrence 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1

Interventions

Whole-Body Irradiation 4 Peripheral Blood Stem Cell Transplantation 4 fludarabine phosphate 3 Mycophenolic Acid 3 Cyclosporine 3 Blood Specimen Collection 3 Rituximab 2 Melphalan 2 Granulocyte Colony-Stimulating Factor 2 Filgrastim 2 Etoposide 2 zanubrutinib 1 thymoglobulin 1 plerixafor 1 amuvatinib 1 Therapeutics 1 Radiotherapy 1 Pentetic Acid 1 Oxycodone 1 O(6)-benzylguanine 1 Music Therapy 1 Moxifloxacin 1 Morphine 1 Minocycline 1 Methadone 1 Magnetic Resonance Spectroscopy 1 Leukapheresis 1 Heparin 1 Fluorescent Antibody Technique 1 Exercise 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06942507 2025-04-30

BRZ-WM

Peking Union Medical College Hospital

Phase NA Not yet recruiting

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡